This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Kinpeygo, budesonide, ...
Want to stay on top of the science and politics driving biotech today? Sign up t...
Third Harmonic Bio will lay off half of its workforce, the biotech has said as i...
A new initiative rolled out under President Donald Trump’s administration is cut...
A federal judge issued a nationwide temporary pause on plans by the NIH to subst...
Insilico also disclosed it’s begun chasing new therapeutic areas in obesity and ...
Consolidated 3-year work plan for the Emergency Task Force (ETF)
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist Sp...
Minutes of the COMP meeting 3-5 December 2024
Human medicines European public assessment report (EPAR): Korjuny, catumaxomab, ...
Merck KGaA is in advanced talks to acquire cancer and rare disease specialist Sp...
Human medicines European public assessment report (EPAR): Hetronifly, serplulima...
Incyte has broken off its immuno-oncology deal with Agenus. The step, which foll...
Get your daily dose of health and medicine every weekday with STAT’s free newsle...
Agenda of the CVMP meeting 11-13 February 2025
Inventiva is going all-in on its metabolic-associated steatohepatitis drug lanif...
Human medicines European public assessment report (EPAR): Jakavi, ruxolitinib, D...
Jakavi-H-C-002464-X-0070-G : EPAR - Assessment report - Variation
Hims & Hers' “Sick of the System” spot not only generated the highest engagement...
Despite the recent failure of an eczema trial, Q32 Bio is sticking with bempikib...
Novartis has brought abelacimab back into the fold. Six years after spinning the...
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abe...
Despite the recent failure of an eczema trial, Q32 Bio is sticking with bempikib...
Will our efforts against H5N1 bind us to a Sisyphean-like struggle of fighting o...